Teva Oncology is one of the top 10 oncology companies in the US. Our portfolio includes multiple offerings for hematologic malignancies and an approved product for supportive cancer care.
JFK Communications was the global PR agency supporting the launch of custersin, an investigational compound for the treatment of hormone resistant prostate cancer. In this capacity, JFK Communications provided:
Pre-launch planning and support
Medical meeting support
Patient advocacy relations